{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T22:51:36Z","timestamp":1774306296941,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T00:00:00Z","timestamp":1491436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukemia (CML) is defined by the presence of t(9;22)(q34;q11.2)\/<jats:italic>BCR\u2010ABL1<\/jats:italic>. Additional chromosomal abnormalities confer an adverse prognosis and are particularly common in the blast phase of CML (CML\u2010BP). <jats:italic>CBFB<\/jats:italic> rearrangement, particularly <jats:italic>CBFB\u2010MYH11<\/jats:italic> fusion resulting from inv(16)(p13.1q22) or t(16;16)(p13.1;q22), is an acute myeloid leukemia (AML)\u2010defining alteration that is associated with a favorable outcome. The co\u2010occurrence of <jats:italic>BCR\u2010ABL1<\/jats:italic> and <jats:italic>CBFB<\/jats:italic> rearrangement is extremely rare, and the significance of this finding remains unclear. We identified 10 patients with myeloid neoplasms harboring <jats:italic>BCR\u2010ABL1<\/jats:italic> and <jats:italic>CBFB<\/jats:italic> rearrangement. The study group included six men and four women with a median age of 51 years (range, 20\u201071 years). The sequence of molecular alterations could be determined in nine cases: <jats:italic>BCR\u2010ABL1<\/jats:italic> preceded <jats:italic>CBFB<\/jats:italic> rearrangement in seven, <jats:italic>CBFB<\/jats:italic> rearrangement preceded <jats:italic>BCR\u2010ABL1<\/jats:italic> in one, and both alterations were discovered simultaneously in one patient. BCR\u2010ABL1 encoded for p210 kD in all cases in which <jats:italic>BCR\u2010ABL1<\/jats:italic> preceded <jats:italic>CBFB<\/jats:italic> rearrangement; a p190 kD was identified in the other three cases. Two patients were treated with the FLAG\u2010IDA regimen (fludarabine, cytarabine, idarubicin, and G\u2010CSF) and tyrosine kinase inhibitors (TKI); seven with other cytarabine\u2010based regimens and TKIs, and one with ponatinib alone. At last follow up (median, 16 months; range 2\u201085), 7 of 10 patients had died. The co\u2010existence of <jats:italic>BCR\u2010ABL1<\/jats:italic> and <jats:italic>CBFB<\/jats:italic> rearrangement is associated with poor outcome and a clinical course similar to that of CML\u2010BP, and unlike <jats:italic>de novo<\/jats:italic> AML with <jats:italic>CBFB<\/jats:italic> rearrangement, suggesting that high\u2010intensity chemotherapy with TKI should be considered in these patients.<\/jats:p>","DOI":"10.1002\/ajh.24710","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T23:16:49Z","timestamp":1488496609000},"page":"520-528","source":"Crossref","is-referenced-by-count":26,"title":["Myeloid neoplasms with concurrent <i>BCR\u2010ABL1<\/i> and <i>CBFB<\/i> rearrangements: A series of 10 cases of a clinically aggressive neoplasm"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5492-1962","authenticated-orcid":false,"given":"Alireza","family":"Salem","sequence":"first","affiliation":[{"name":"Department of Hematopathology The University of Texas, MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas, MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas, MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang O.","family":"Huh","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas, MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas, MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas, MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas, MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas, MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajyalakshmi","family":"Luthra","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas, MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas, MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas, MD Anderson Cancer Center Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,4,6]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"32","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Vardiman JW","year":"2008"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.701739"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00207-7"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24275"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26679"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-690230"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.231"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.96"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2592-3"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.6"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0128-2"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.96"},{"key":"e_1_2_7_14_1","first-page":"110","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Arber DA","year":"2008"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800829"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1309\/PGNT8LGN9AR4QVAJ"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11357"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-442772"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1309\/3HFE16DKMB1DBFMN"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00161-9"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(92)90154-Z"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-011-0854-3"},{"key":"e_1_2_7_23_1","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele J","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/S0046-8177(03)00412-X"},{"key":"e_1_2_7_25_1","volume-title":"ISCN (2013): An International System for Human Cytogenetic Nomenclature","author":"Shaffer LG","year":"2013"},{"key":"e_1_2_7_26_1","first-page":"135","article-title":"TaqMan reverse transcriptase\u2010polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr\u2010abl transcript type","volume":"335","author":"Luthra R","year":"2006","journal-title":"Methods Mol Biol."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403135"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23652"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.88"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830270118"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(92)90129-V"},{"key":"e_1_2_7_32_1","first-page":"381","article-title":"Inversion of chromosome 16 and dysplastic eosinophils in accelerated phase of chronic myeloid leukemia","volume":"6","author":"Enright H","year":"1992","journal-title":"Leukemia."},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(92)90086-N"},{"key":"e_1_2_7_34_1","first-page":"628","article-title":"The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia","volume":"9","author":"Anastasi J","year":"1995","journal-title":"Leukemia."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(92)90251-3"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02821939"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(97)00070-2"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00199-0"},{"key":"e_1_2_7_39_1","first-page":"1333","article-title":"The effect of imatinib mesylate on patients with Philadelphia chromosome\u2010positive chronic myeloid leukemia with secondary chromosomal aberrations","volume":"9","author":"Mohamed AN","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3709"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-030312"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24710","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:33:14Z","timestamp":1695515594000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1002\/ajh.24710"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24710","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,6]]}}}